{"id":16951,"date":"2023-07-03T15:56:56","date_gmt":"2023-07-03T13:56:56","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=16951"},"modified":"2024-12-11T19:03:41","modified_gmt":"2024-12-11T18:03:41","slug":"revision-des-criteres-de-reponse-iwg-des-smd-de-haut-risque","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/revision-des-criteres-de-reponse-iwg-des-smd-de-haut-risque\/","title":{"rendered":"R\u00e9vision des crit\u00e8res de r\u00e9ponse IWG des SMD de haut risque"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. : HematoStat.net ; 4 (2) : R78<\/p>\n<p><em><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36724453\/\">Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023 27;141(17):2047-2061. <\/a><\/em><\/p>\n<p><strong>R\u00e9sum\u00e9 de l\u2019article<\/strong><\/p>\n<p>Nous retiendrons plusieurs consensus d\u2019experts (IWG) importants de cette mise \u00e0 jour des crit\u00e8res de r\u00e9ponse aux traitements des SMD de haut risque en comparaison des crit\u00e8res de r\u00e9ponse IWG 2006 : (1) une baisse du seuil de l\u2019h\u00e9moglobine \u00e0 10g\/dL pour d\u00e9finir les r\u00e9ponses compl\u00e8tes (EC) ; (2) la disparition du crit\u00e8re mCR (clairance blastique sans am\u00e9lioration des cytop\u00e9nies) ; (3) des nouvelles cat\u00e9gories de r\u00e9ponse \u00ab CR<sub>H<\/sub> \u00bb et \u00ab CR<sub>L<\/sub> \u00bb associant une clairance blastique et l\u2019am\u00e9lioration des cytop\u00e9nies \u00e0 diff\u00e9rents degr\u00e9s.<\/p>\n<p><strong>Dans nos pratiques<\/strong><\/p>\n<p>La plupart des crit\u00e8res de r\u00e9ponse utilis\u00e9s pour \u00e9valuer la r\u00e9ponse th\u00e9rapeutique des SMD de haut risque sont bas\u00e9s sur l\u2019IWG 2006. Cette actualisation est donc importante \u00e9tant donn\u00e9 : i\/ l\u2019importance des essais cliniques dans cette population de SMD haut risque qui reste un challenge th\u00e9rapeutique et ii\/ la n\u00e9cessit\u00e9 d\u2019une harmonisation des crit\u00e8res objectifs de r\u00e9ponse.<\/p>\n<p><strong>Le regard du biostatisticien<\/strong><\/p>\n<p>Pas de biostatistiques pour cette \u00e9tude. On retiendra que ce panel d\u2019experts se sont bas\u00e9s sur 5 points importants pour reclassifier les crit\u00e8res de r\u00e9ponse :<\/p>\n<ul>\n<li>de d\u00e9velopper dans la mesure du possible des recommandations sur la base de donn\u00e9es av\u00e9r\u00e9es ;<\/li>\n<li>de prendre en compte l\u2019applicabilit\u00e9 de ces crit\u00e8res partout dans le monde, en consid\u00e9rant les ressources (comme la disponibilit\u00e9 de tests, d\u2019outils de mesures, etc.) ;<\/li>\n<li>mettre l\u2019accent sur des donn\u00e9es valid\u00e9es notamment sur la r\u00e9ponse compl\u00e8te ou <em>endpoints <\/em>similaires \u00e0 la RC (comme la maladie r\u00e9siduelle) ;<\/li>\n<li>la praticit\u00e9 intra et inter-op\u00e9rateur et la coh\u00e9rence de l\u2019application de ces crit\u00e8res ;<\/li>\n<li>et enfin, tenir compte de l\u2019\u00e9volution des syst\u00e8mes de classifications, surtout avec la reconnaissance du spectre de maladie my\u00e9lo\u00efde continue bas\u00e9e sur les donn\u00e9es biologiques plut\u00f4t que des seuils de blastes.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":16952,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[],"ppma_author":[459],"class_list":["post-16951","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","author-lin-pierre-zhao"],"aioseo_notices":[],"authors":[{"term_id":459,"user_id":0,"is_guest":1,"slug":"lin-pierre-zhao","display_name":"Lin-Pierre ZHAO","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2023-03-29-a-12.52.50-1.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2023-03-29-a-12.52.50-1.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue. <br>\r\nChef de clinique assistant <br>\r\n<strong>Liens d'int\u00e9r\u00eats au 06\/03\/2024 : <\/strong>l'auteur d\u00e9clare ne pas avoir de liens d'int\u00e9r\u00eats. <br>\r\n<strong>Liens d'int\u00e9r\u00eats au 01\/01\/2024 : <\/strong>l'auteur d\u00e9clare ne pas avoir de liens d'int\u00e9r\u00eats. <br>\r\n<strong>Correspondance : <\/strong>Service H\u00e9matologie S\u00e9niors - Tr\u00e8fle 4 | H\u00f4pital Saint-Louis | Universit\u00e9 Paris Cit\u00e9\r\nInserm U1160 | Institut de Recherche Saint-Louis\r\n1 avenue Claude Vellefaux, 75010 Paris.<br>"}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16951"}],"version-history":[{"count":2,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16951\/revisions"}],"predecessor-version":[{"id":18252,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16951\/revisions\/18252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media\/16952"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16951"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}